First Quarter 2022 Earnings April 27, 2022

Fluid & Metering

### Health & Science

LUIDHITDH

Fire & Safety / Diversified

68.61



Trusted Solutions, Improving Lives™



# **IDEX Business Overview**

# Q1 2022 Financial Performance

Segment Performance

2022 Guidance Summary

Q&A



# **Replay Information**

- Dial toll-free: 877.660.6853
- International: 201.612.7415
- Conference ID: #13724803
- Log on to: www.idexcorp.com



# **Cautionary Statement**

#### Cautionary Statement Under the Private Securities Litigation Reform Act; Non-GAAP Measures

This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, the Company's expected organic sales growth and expected earnings per share, and the assumptions underlying these expectations, plant and equipment capacity for future growth and the anticipated timing and effects of planned facility expansion, the duration of supply chain challenges, anticipated future acquisition behavior and capital deployment, availability of cash and financing alternatives, the anticipated timing of the closing of the Company's acquisition of KZValve and the anticipated benefits of the Company's acquisitions of Airtech Group, Inc., US Valve Corporation and related entities ("Airtech"), Nexsight and KZValve, and are indicated by words or phrases such as "anticipates," "estimates," "plans," "guidance," "expects," "projects," "forecasts," "should," "could," "will," "management believes," "the Company believes," "the Company intends" and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this presentation. The risks and uncertainties include, but are not limited to, the following: the impact of health epidemics and pandemics, including the COVID-19 pandemic, and the impact of related governmental actions, on the Company's ability to operate its business and facilities, on its customers, on supply chains and on the U.S. and global economy generally; economic and political consequences resulting from terrorist attacks and wars, including Russia's invasion of Ukraine and the global response to this invasion, which, along with the ongoing effects of the COVID-19 pandemic, could have an adverse impact on the Company's business by creating disruptions in the global supply chain and by potentially having an adverse impact on the global economy; levels of industrial activity and economic conditions in the U.S. and other countries around the world; pricing pressures and other competitive factors and levels of capital spending in certain industries. all of which could have a material impact on order rates and the Company's results; the Company's ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which the Company operates; developments with respect to trade policy and tariffs; interest rates; capacity utilization and the effect this has on costs; labor markets; supply chain backlogs, including risks affecting component availability, labor inefficiencies and freight logistical challenges; market conditions and material costs; and developments with respect to contingencies, such as litigation and environmental matters. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the "Risk Factors" section included in the Company's most recent annual report on Form 10-K and the Company's subsequent quarterly reports filed with the Securities and Exchange Commission ("SEC") and the other risks discussed in the Company's filings with the SEC. The forward-looking statements included here are only made as of the date of this news release, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.

This presentation contains non-GAAP financial information. Reconciliations of non-GAAP measures are included either in this presentation or our earnings release for the three-month period ending March 31, 2022, which is available on our website.



Trusted Solutions, Improving Lives™

# **Business Update**



**IDEX Proprietary & Confidential** 

# **IDEX** Overview



## **Capitalizing on Robust Demand**

- Record Orders, Sales, and Backlog
- Organic sales growth of 12% doubles expectations
- Growth across all three segments



## **Driving Operational Excellence**

- Managing the supply chain environment
- Continued price capture amid inflation
- Productivity initiatives yielding benefits



## **Continuing to Deploy Capital**

- Announcement of KZ Valve and closing of Nexsight
- Deployed \$28 million for share repurchases
- Resource investments to drive growth



## Financials



# **IDEX Q1 2022 Financial Performance**




**Adjusted Operating Margin\*** 

+70 bps

25.0%

Q1 2022

### Adjusted Earnings per Share\*




Trusted Solutions, Improving Lives™

### **IDEX Proprietary & Confidential**

24.3%

Q1 2021

# 2022 Adjusted Operating Income Walk



Trusted Solutions, Improving Lives™

#### **IDEX Proprietary & Confidential**

# **IDEX Segment Performance**



### Fluid & Metering Technology

Q1 Revenue \$272M / 36% of Total

 Positive industrial book & ship •Strong Water & Ag market Improving Energy

Organic Orders V%	14%
Organic Sales V%*	11%
Adj Op Margin vbps*	+300



### Health & Science Technology

*Q1 Revenue \$315M / 42% of Total* 

•Strong secular growth trends •Genetic sequencing / Semi wins Project funnel growing

Organic Orders V%	21%
Organic Sales V%*	16%
Adj Op Margin vbps*	(40)

Ex Acquisition-related intangible amortization\*



### Fire & Safety / Diversified

*Q1 Revenue \$165M / 22% of Total* 

Dispensing strong performance

- Industrial/Energy offset Auto
- •Lagging North America Fire

Organic Orders V%	12%
Organic Sales V%*	5%
Adj Op Margin vbps*	(340)

\*This presentation contains non-GAAP financial information. Reconciliations of non-GAAP measures are included either in this presentation or our earnings release for the three-month period ending March 31, 2022, which is available on our website.

+90

# 2022 Guidance Summary

		Second Quarter	Full Year		
		Current Guidance	Prior Guidance	Current Guidance	
Organic Sales %	Organic*	8-9%	5-8%	6-8%	
Operating Margin %	Reported	23-23.5%	~24%	~24%	
Earnings per Share	Reported Adjusted*	\$1.69-\$1.74 \$1.85-\$1.90	\$6.70-\$7.00 \$7.33-\$7.63	\$6.87-\$7.00 \$7.50-\$7.63	
<u>Other Modeling Items:</u> FX Impact on Sales		-2% <sup>(1)</sup>	-1% <sup>(2)</sup>	-1% <sup>(1)</sup>	
Acquisition impact on Sales		6%	2%	4%	
Corporate Costs		~\$20 million	~\$80 million	~\$80 million	
Tax Rate Capital Expenditures		22.5%	22.5% \$90+ million	22.5% \$90+ million	
Free Cash Flow % of Adjusted	Net Income		~105%	~105%	

Earnings per share estimates exclude all future acquisitions and any future restructuring expenses

(1) Based on 3/31/2022 FX rate(2) Based on 12/31/2021 FX rate



#### **IDEX Proprietary & Confidential**

# Appendix



# Fluid & Metering Technologies



Q1 Sales Mix:	Organic	11%
	Acquisition	2%
	FX	<u>(1%)</u>
	Reported Sales	12%

#### Q1 Highlights:


- Strong Industrial day rates
- □ Agriculture demand remains high on increased crop prices
- □ Increasing Municipal Water project activity
- **□** Energy improving on higher oil and home heating fuel price support
- Strong volume and productivity driving margin expansion

### Strong growth and productivity



IDEX Proprietary & Confidential

## Health & Science Technologies



#### Q1 Highlights:

Q1 Sales Mix:	Organic	16%
	Acquisition	11%
	FX	<u>(1%)</u>
	Reported Sales	26%

#### Strong Life Sciences, Analytical Instrumentation, Semiconductor, Food & Pharma


- Continued wins in Genetic Sequencing, Broadband, and Additive Manufacturing
- Excluding amortization tied to Airtech, Operating margin expanded 90 bps
- □ Volume leverage partly offset by discretionary/resource spend driving margin expansion



### Strong growth drives profitability

IDEX Proprietary & Confidential

## Fire & Safety / Diversified Products



Q1 Sales Mix:	Organic	5%
	FX	<u>(2%)</u>
	Reported Sales	3%

#### Q1 Highlights:

- Dispensing strong demand within paint markets globally
- BAND-IT Energy and Industrial market strength more than offsets Automotive delays
- □ Fire & Rescue continues to lag due to supply chain issues with OEMs
- □ Margin compression largely driven by unfavorable price/cost
- □ Expect price/cost improvement in second half 2022



### Supply Chain factors continue to temper segment performance

This information reconciles non-GAAP measures (denoted with a \*) with the most directly comparable GAAP measure. (dollars in millions, except per share amounts)

#### Reconciliation of the Change in Net Sales to Organic Net Sales

	Thre	Three Months Ended March 31, 2022					
	FMT	HST	FSDP	IDEX			
Change in net sales	12%	26%	3%	15%			
<ul> <li>Net impact from acquisitions/divestitures</li> </ul>	2%	11%	%	5%			
- Impact from foreign currency	(1%)	(1%)	(2%)	(2%)			
Change in organic net sales	11%	16%	5%	12%			



This information reconciles non-GAAP measures (denoted with a \*) with the most directly comparable GAAP measure. (dollars in millions, except per share amounts)

#### Reconciliation of Reported-to-Adjusted Operating Income and Margin

		Three Months Ended March 31,								
		2022						2021		
	FMT	HST	FSDP	Corporat	IDEX	FMT	HST	FSDP	Corporat	IDEX
Reported operating income (loss)	\$ 80.4	\$ 83.6	\$ 40.5	\$ (16.9)	\$ 187.6	\$ 62.9	\$ 66.6	\$ 44.6	\$ (18.6)	\$ 155.5
+ Restructuring expenses and asset impairments		_	_	_	_	0.9	0.6	0.1	0.6	2.2
+ Fair value inventory step-up charge						0.7				0.7
Adjusted operating income (loss)	\$ 80.4	\$ 83.6	\$ 40.5	\$ (16.9)	\$ 187.6	\$ 64.5	\$ 67.2	\$ 44.7	\$ (18.0)	\$ 158.4
Net sales (eliminations)	\$ 272.0	\$ 315.2	\$ 164.7	\$ (0.8)	\$ 751.1	\$ 243.3	\$ 250.4	\$ 159.5	\$ (1.2)	\$ 652.0
Reported operating margin	29.5%	26.5%	24.6%	n/m	25.0%	25.8%	26.6%	27.9%	n/m	23.9%
Adjusted operating margin	29.5%	26.5%	24.6%	n/m	25.0%	26.5%	26.9%	28.0%	n/m	24.3%

Three Months Ended March 31



This information reconciles non-GAAP measures (denoted with a \*) with the most directly comparable GAAP measure. (dollars in millions, except per share amounts)

#### Reconciliation of Reported-to-Adjusted Net Income

	Three Months Ended March 31,			
	2022			2021
Reported net income attributable to IDEX	\$	140.0	\$	112.7
+ Restructuring expenses and asset impairments		_		2.2
+ Tax impact on restructuring expenses and asset impairments		_		(0.5)
+ Fair value inventory step-up charge		_		0.7
+ Tax impact on fair value inventory step-up charge		_		(0.2)
- Gains on sales of assets		(2.7)		_
+ Tax impact on gains on sales of assets		0.6		—
+ Acquisition-related intangible asset amortization		15.3		11.0
+ Tax impact on acquisition-related intangible asset amortization		(3.4)		(2.5)
Adjusted net income attributable to IDEX	\$	149.8	\$	123.4



This information reconciles non-GAAP measures (denoted with a \*) with the most directly comparable GAAP measure. (dollars in millions, except per share amounts)

#### Reconciliation of Reported-to-Adjusted EPS

	Three Months Ended March 31,			March 31,
		2022		2021
Reported diluted EPS attributable to IDEX	\$	1.83	\$	1.48
+ Restructuring expenses and asset impairments		_		0.03
+ Tax impact on restructuring expenses and asset impairments		_		(0.01)
+ Fair value inventory step-up charge		_		0.01
+ Tax impact on fair value inventory step-up charge		_		_
- Gains on sales of assets		(0.03)		_
+ Tax impact on gains on sales of assets		0.01		_
+ Acquisition-related intangible asset amortization		0.20		0.14
+ Tax impact on acquisition-related intangible asset amortization		(0.05)		(0.03)
Adjusted diluted EPS attributable to IDEX	\$	1.96	\$	1.62
Diluted weighted average shares outstanding		76.4		76.3



This information reconciles non-GAAP measures (denoted with a \*) with the most directly comparable GAAP measure. (dollars in millions, except per share amounts)

Reconciliation of Cash Flows from Operating Activities to Free Cash Flow

	Three Months Ended March 31,				
		2022		2021	
Cash flows from operating activities	\$	79.7	\$	109.3	
- Capital expenditures		16.1		14.6	
Free cash flow	\$	63.6	\$	94.7	



This information reconciles non-GAAP measures (denoted with a \*) with the most directly comparable GAAP measure. (dollars in millions, except per share amounts)

#### Reconciliation of Estimated 2022 EPS to Adjusted EPS Attributable to IDEX

	Guidance	
	Second Quarter 2022	Full Year 2022
Estimated EPS attributable to IDEX	\$1.69 - \$1.74	\$6.87 - \$7.00
+ Acquisition-related intangible asset amortization	\$0.22	\$0.85
+ Tax impact on acquisition-related intangible asset amortization	\$(0.06)	\$(0.20)
- Gains on sales of assets	—	\$(0.03)
+ Tax impact on gains on sales of assets		\$0.01
Estimated adjusted EPS attributable to IDEX	\$1.85 - \$1.90	\$7.50 - \$7.63

